Advertisement

Search Results

Advertisement



Your search for all items matches 35420 pages

Showing 151 - 200


ASCO Names 2025 Q1, Q2 FASCO Recipients

Launched in 2007 and formerly called the ASCO Statesman Award, the FASCO distinction honors members for their extraordinary volunteer service, engagement, and dedication to American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO). Listed here are the FASCO ...

solid tumors

Dendrimer-Based SN38 Nanoparticle Shows Favorable Safety and Activity in Advanced Solid Tumors

In an early-phase study reported in the Journal of Clinical Oncology, Liu et al evaluated the safety and preliminary efficacy of DEP-SN38, a polylysine-based dendrimer-nanoparticle delivery platform for the topoisomerase 1 inhibitor SN38, in patients with advanced solid tumors. SN38 is the active...

OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight

Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally. It is the largest single donation ever made to a ...

cns cancers

Glioblastoma: Dual Immunotherapy Plus Radiotherapy in Newly Diagnosed MGMT-Unmethylated Disease

The combination of ipilimumab and nivolumab plus radiation therapy did not lead to an improvement in progression-free survival compared with radiation therapy and temozolomide for patients with newly diagnosed MGMT-unmethylated glioblastoma, according to phase II results of the NRG-BN007 trial...

survivorship

Bridging the Gap: Stronger Primary Care Ties May Improve Cancer Survivorship

Optimal continued care for patients with cancer may require greater involvement from primary care clinicians, according to the results of an observational study published in Current Oncology.  The study highlighted certain challenges in cancer care, including patient-centered coordination and...

bladder cancer

New Drug-Releasing System Eliminates Bladder Cancer in Over 80% of Patients in a Phase II Trial

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in the phase II SunRISe-1 trial (ClinicalTrials.gov identifier NCT04640623) for individuals with high-risk non–muscle-invasive bladder cancer whose disease had previously resisted treatment. In the majority of cases, the...

prostate cancer

EBRT With Focal Boost in Localized Prostate Cancer: 10-Year Follow-up

As reported in the Journal of Clinical Oncology by Guricová et al, 10-year outcomes of the Dutch-Belgian phase III FLAME trial showed continued benefit of a focal radiotherapy boost to the intraprostatic tumor in patients receiving external-beam radiotherapy (EBRT) for localized prostate cancer....

breast cancer

Clinically Significant Fatigue and Inflammation in Breast Cancer Survivors

Clinically significant fatigue was associated with increased inflammation in breast cancer survivors, according to study findings published in BMC Women's Health. The study authors also suggested that an increase in inflammatory markers from clinical fatigue could lead to breast cancer recurrence.  ...

colorectal cancer
issues in oncology

Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows

The introduction of artificial intelligence (AI) to assist colonoscopies may be linked to a reduction in the ability of endoscopists to detect adenomas in the colon without AI assistance, according to a paper published by Budzyń et al in The Lancet Gastroenterology & Hepatology. Colonoscopy...

breast cancer

RSNA Challenge AI Models Enhance Mammography Detection of Invasive Breast Cancer

Various artificial intelligence (AI) algorithms submitted as part of a challenge demonstrated the ability to identify different breast cancers during screening mammography, according to the results of a study published in Radiology. Ensemble models of the top submitted algorithms indicated that the ...

breast cancer
covid-19

Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods

In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre–COVID-19 period, with no significant difference in recurrence or progression being observed. Study ...

colorectal cancer

Age Threshold for Survival Benefit of Adding Oxaliplatin to Adjuvant Chemotherapy in Stage II and III Colorectal Cancer

In a Korean retrospective study reported in JAMA Network Open, Bong et al found that the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy was associated with an overall survival benefit in patients with stage III colorectal cancer aged ≤ 70 years but not in those aged > 70 ...

Best of ASCO 20th Anniversary: Advancing Medicine and Patient Care, ASCO Style!

For the 20th year in a row, major advances in cancer research and practice-changing clinical trials from the 2025 ASCO Annual Meeting (ASCO25) were presented at the ASCO-licensed Best of ASCO meeting, held on July 18–19, 2025, in Beirut, Lebanon. It was indeed a great celebration and commitment to...

prostate cancer

Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?

In a substudy of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that baseline prostate-specific membrane antigen (PSMA)–positron-emission tomography (PET) total tumor volume (TTV) was prognostic for overall survival and predictive for a beneficial effect on ...

breast cancer

Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy

In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estrogen receptor–positive, HER2-negative breast cancer with high-risk disease on the basis of genomic...

John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director

John C. Byrd, MD, FASCO, an internationally lauded researcher and clinical specialist in hematologic malignancies, has been appointed Director of UPMC Hillman Cancer Center, effective November 2025. In his role as Director, Dr. Byrd will be responsible for all aspects of the University of...

issues in oncology

Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country

Remarkable advances in treatments for cancer over the past 2 decades are enabling increased personalized care for patients with the disease. However, the growing complexity of treatment methods, including targeted therapy, immunotherapy, and advanced oral therapy, make it challenging for medical...

survivorship

Childhood Cancer Survivors and Long-Term Risks for Health Conditions: New Data

Some survivors of childhood cancers face a continued elevated risk of premature mortality, new cancers, chronic conditions, and other adverse health conditions as they grow older, according to new findings published in the Journal of Clinical Oncology.  An increased risk for cancer and other...

lung cancer

Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach

In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus...

kidney cancer
genomics/genetics

Genomics-Guided Tool to Inform Treatment of Advanced Kidney Cancers

Results from a recent study may help to explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind tool to guide treatment decisions for patients with advanced kidney cancers. The collaborative work ...

lung cancer

Web Tool Seeks to Reduce State Lung Cancer Mortality Rates

Experts from the National Lung Cancer Roundtable have created a customizable, web-based platform that allows groups and local leaders to develop state-based action plans for reducing lung cancer mortality rates. The platform, called the SBI Planning Tool, allows users to explore real-world...

multiple myeloma

Case 3: Optimal Sequencing of T-Cell–Redirected Therapies

This is Part 3 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with high-risk...

multiple myeloma

Case 2: Role of T-Cell–Redirected Therapies in Elderly Patients With Relapsed/Refractory Multiple Myeloma

This is Part 2 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with relapsed...

multiple myeloma

Case 1: Role of ASCT in the Era of Quadruplet Induction and T-Cell–Redirected Therapies

This is Part 1 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with newly...

lung cancer

Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations

Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD)–activating mutations, as...

geriatric oncology

Survival in Older Patients With Cancer and Diabetes: GLP-1 RAs vs Other Glucose-Lowering Drugs

A retrospective cohort study published in JAMA Network Open found glucagon-like peptide-1 (GLP-1) receptor agonists to be associated with lower all-cause mortality than dipeptidyl peptidase-4 (DPP-4) inhibitors, with no significant difference from sodium-glucose cotransporter-2 (SGLT-2) inhibitors, ...

issues in oncology

Smoking Cessation in Cancer Care: Challenges and Opportunities

Based on the results of a cohort study reported in JAMA Network Open, smoking worsened both cancer symptom burden and severity. However, Rieth et al noted that oncologic surgery may present a unique teachable moment for smoking cessation, as patients appeared to be highly motivated to quit. The...

gastrointestinal cancer
genomics/genetics

Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers

For patients with gastrointestinal (GI) cancers, chemotherapy can sometimes cause severe, even life-threatening side effects in those who carry certain genetic variants that may impact how their bodies process the drugs used to treat their disease. Testing for variants in two genes before starting...

gynecologic cancers

Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume

In a cross-sectional study reported in JAMA Network Open, Abel et al found that higher rates of neoadjuvant chemotherapy (NACT) and a higher annual volume of cytoreductive surgery were associated with better survival outcomes in patients treated at Commission on Cancer–accredited cancer programs in ...

multiple myeloma

Novel Single-Cell Sequencing Blood Test for Multiple Myeloma

Researchers at Dana-Farber Cancer Institute have developed a blood test that may alter the diagnosis and monitoring of multiple myeloma and its precursor conditions. The new method, known as SWIFT-seq, uses single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a...

myelodysplastic syndromes

Real-World Study Highlights Gaps in Hypomethylating Agent Treatment for MDS

Researchers have identified age-, sex-, and race-related disparities around treatment with hypomethylating agents for patients with myelodysplastic syndromes in the United States. The receipt of hypomethylating agents was found to favor younger, male, White patients, according to findings published ...

pancreatic cancer

Combination Therapies for Metastatic or Recurrent Pancreatic Cancer Under Study

In an interim analysis of a Japanese phase II/III trial (GENERATE, JCOG1611) reported in the Journal of Clinical Oncology, Ohba et al compared the survival benefit of mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, oxaliplatin) or S-IROX (S-1, irinotecan, oxaliplatin) vs nab-paclitaxel...

gynecologic cancers

Chemotherapy Regimens Compared in High-Grade Serous Ovarian Cancer With No BRCA Mutation

In a phase III trial (EPIK-O/ENGOT-ov61) reported in the Journal of Clinical Oncology, Konstantinopoulos et al compared the survival outcomes of alpelisib plus olaparib vs single-agent chemotherapy in patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) with no...

lung cancer

Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer

In patients with small cell lung cancer, second-line treatment with the bispecific T-cell engager tarlatamab-dlle (which targets the delta-like ligand 3 [DLL3]) vs standard-of-care chemotherapy appeared to significantly improve overall survival, progression-free survival, and patient-reported...

cns cancers

Protease Activator Approved by the FDA for Diffuse Midline Glioma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso) a protease activator, for adult and pediatric patients aged 1 year and older with diffuse midline glioma harboring an H3 K27M mutation who have progressive disease after prior therapy. This...

kidney cancer

RCC: Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes

Genetic testing may be the only way to differentiate between common and more rare subtypes of renal cell carcinoma (RCC) to prevent misdiagnoses, according to the results of a study published in Human Pathology.  Mucinous tubular and spindle cell carcinoma (MTSCC) was found to share many...

gynecologic cancers

Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers

In an Australian–New Zealand phase II trial (MoST-CIRCUIT) reported in JAMA Oncology, Gao et al found that the combination of nivolumab and ipilimumab showed “encouraging activity” in patients with advanced ovarian and endometrial clear cell cancers. Study Details Twenty-eight patients with...

colorectal cancer

Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years

It has been widely reported that colorectal cancer incidence has been increasing among younger adults under age 50 since the mid-1990s, with a consistent annual increase of 2% among adults aged 20 to 39. This increase prompted the American Cancer Society (ACS), in 2018, and the United States...

geriatric oncology

Advancing Geriatric Oncology: Where We Have Been and Where We Are Going

The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unprepared. The shortage of oncologists, along with many experienced clinicians retiring early, has...

ASCO Edge Launches for All Members

ASCO has announced the launch of ASCO Edge, an online oncology practice and operations management educational series developed by oncology professionals for oncology professionals.  ASCO Edge is a member-only benefit that will provide ASCO members with education and tools to effectively manage the...

leukemia

Immunoglobulin Replacement Therapy and Infection Risks in CLL

Immunoglobulin replacement therapy did not lead to a reduction in the risk for serious infections leading to hospitalizations for patients with chronic lymphocytic leukemia (CLL), according to the results of a real-world Australian cohort study published in Blood Advances. This finding is at odds...

issues in oncology
supportive care

Perceived Dermatologic Side Effects of Cancer Treatment: Pilot Survey Findings

A recent study published by Menta et al in the Journal of Drugs in Dermatology found that many people misunderstand how common skin, hair, and nail side effects are during cancer treatment—and those fears may lead some to avoid or delay care. Conducted by researchers at the George Washington...

cns cancers

Pediatric Gliomas: Early Research on Targeted Therapies

A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common type of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and these gliomas may be sensitive to...

prostate cancer

Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature

In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signature–positive metastatic castration-resistant prostate cancer (mCRPC). Study Details The multicenter...

integrative oncology

Ayurveda in Cancer Care

Guest Editor’s Note: Ayurveda, the traditional medical system that originated in India, focuses on improving overall well-being through self-care, diet, and herbal formulations. There is a growing patient interest in using Ayurveda for symptom control and to improve quality of life. In this...

lung cancer

Ultraprocessed Food Consumption May Be Linked to Increased Lung Cancer Risk

Greater consumption of ultraprocessed food is associated with an increased risk of developing either small cell or non–small cell lung cancer, according to findings published in Thorax.  "Over the past 2 decades, the consumption of ultraprocessed food has significantly increased worldwide,...

cardio-oncology

Investigating the Mechanisms of Cardiovascular Adverse Events Linked to Certain Cancer Treatments

The true upside of the many advances in cancer treatment is clear. Approximately 18.6 million people in the United States have a history of cancer, and the number of cancer survivors is expected to exceed 22 million by the year 2035.1However, one downside affecting many of these individuals is the...

covid-19

Outcomes Associated With COVID-19 Infection in Patients With Cancer

As reported in JAMA Oncology by Rini et al, the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) has identified outcomes associated with COVID-19 in patients with cancer. Study Details Between May 2020 and February 2022, the study enrolled adult patients from sites participating ...

prostate cancer
issues in oncology

Prostate Cancer: One in Six Grade Group 1 Cases Linked to Higher-Risk Disease

Patients classified with "grade group 1" prostate cancer face a wide range of long-term outcomes, according to findings from a study published in JAMA Oncology. Investigators revealed that as many as one in six men with grade group 1 prostate cancers have intermediate- or high-risk disease when...

cns cancers

Pediatric CNS Tumors: Long-Term Survival and Cure Fraction Estimates

As reported in The Lancet Oncology by Hoogendijk et al, the EUROCARE-6 population-based study has provided long-term survival rates and cure fraction estimates for pediatric patients with central nervous system (CNS) tumors across 31 European countries. Study Details The study involved data from...

Advertisement

Advertisement




Advertisement